Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow INAB by emailGet an email when INAB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INAB, unsubscribe in one click. Privacy
📣 What INAB Says Is Next
second half of 2026 · “Remain on track to report initial in vivo preclinical data in the second half of 2026.”
Company press release, Aug 6, 2026 · SEC filing
this year · “We are pleased to remain on track for reporting initial in vivo data this year,” said William Ho, Chief Executive Officer and co-founder of IN8bio.”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “Advanced next-generation gamma delta (γδ) T cell engager (TCE) platform demonstrating a novel mechanism for γδ T cell expansion, deep target cell depletion, and favorable cytokine profile; Initial in vivo data expected in the second half of 2026”
Company press release, Aug 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full INAB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.